Few studies have been published reporting the efficiency of CAR T cells in preventing metastatic prostate cancer (mPCa) mainly by targeting prostate-specific membrane antigen (PSMA), which is expressed in prostate cancer cells. This evidence concerns the gene FOLH1 and prostate cancer.